Amicus Therapeutics (NASDAQ:FOLD) : Amicus Therapeutics (NASDAQ:FOLD) had a healthy money flow of $1.1 million into the stock during the Wednesdays trading session. The value of bullish trades on upticks was $2.49 million, whereas, investors only sold shares worth $1.4 million on downticks. The stock closed the day with an up-down ratio of 1.79.The money flow in the block trades to the tune of $0.36 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.36 million worth of transactions were on upticks. Amicus Therapeutics (NASDAQ:FOLD) stock slid $0.01 intraday and traded at 5.42, a change of -0.18% over previous days close. However, for the week, the company shares are -0.55% compared to previous weeks close.
In an insider trading activity, Rosenberg Ellen, officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc had purchased 15,000 shares on June 2, 2016 in a transaction. The price per share was $7.67 and the total amount of the disclosed transaction was $115,050.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices. Currently the company Insiders own 8.3% of Amicus Therapeutics shares according to the proxy statements.
The company shares have dropped -61.27% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $18.83 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $6.49 and the 200 Day Moving Average price is recorded at $7.29. Amicus Therapeutics (NASDAQ:FOLD): The stock opened at $5.55 on Wednesday but the bulls could not build on the opening and the stock topped out at $5.55 for the day. The stock traded down to $5.26 during the day, due to lack of any buying support eventually closed down at $5.42 with a loss of -0.18% for the day. The stock had closed at $5.43 on the previous day. The total traded volume was 2,357,260 shares.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.